Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 20:20:19-25.
doi: 10.1016/j.amsu.2017.06.026. eCollection 2017 Aug.

Effect of adjuvant chemotherapy after pulmonary metastasectomy on the prognosis of colorectal cancer

Kazu Shiomi  1 , Masanori Naito  2 , Takeo Sato  2 , Takatoshi Nakamura  2 , Hiroyasu Nakashima  1 , Masahito Naito  1 , Masashi Mikubo  1 , Yoshio Matsui  1 , Masahiko Watanabe  1 , Yukitoshi Satoh  1
Affiliations

Effect of adjuvant chemotherapy after pulmonary metastasectomy on the prognosis of colorectal cancer

Kazu Shiomi et al. Ann Med Surg (Lond). .

Abstract

Background: Adjuvant chemotherapy after resection of colorectal cancer (CRC) lung metastases may reduce recurrences and improve survival. We investigated the effects of adjuvant chemotherapy after curative resection of lung CRC metastases on prognosis.

Methods: We retrospectively reviewed records of our patients undergoing pulmonary metastasectomy from CRC between January 2000-March 2014. Data were analyzed with Kaplan-Meier survival analysis and Cox proportional hazards models.

Results: One-hundred (56 men; median age, 66 years) of 128 consecutive patients who underwent complete resection for first lung colorectal metastases were analyzed. Postoperative 5-year rates of overall survival (OS) and relapse-free survival (RFS) were 76% and 41%, respectively. Adjuvant chemotherapy strongly affected RFS and OS by multivariable analysis compared to surgery alone (RFS: HR, 0.49; 95% CI, 0.27-0.88; P = 0.016 and OS: HR, 0.35; 95% CI, 0.14-0.81; P = 0.014). Similar effects of adjuvant chemotherapy occurred in subgroups respectively classified according to number of lung metastases and preoperative serum carcinoembryonic antigen (CEA) level.

Conclusions: Adjuvant chemotherapy after curative resection of lung metastases might strongly affect the prognosis of metastatic CRC patients. Even patients with single metastatic lesions and normal preoperative CEA level appeared to receive benefits from such chemotherapy. Narrowing of suitable candidates by predicting the effects of systemic chemotherapy and prospective randomized studies are needed.

Keywords: Adjuvant chemotherapy; Colorectal cancer; Pulmonary metastasectomy; Pulmonary metastasis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Relapse-free survival (A) and overall survival (B) after resection of lung colorectal metastases in patients with and without adjuvant chemotherapy.
Fig. 2
Fig. 2
Relapse-free survival (RFS) after resection of lung colorectal metastases. (A) RFS according to the number of metastases and pre-thoracotomy serum carcinoembryonic antigen (CEA) level. (B) RFS in patients with versus without adjuvant chemotherapy in the subgroup of patients with a single metastatic lesion and a normal preoperative CEA level. (C) RFS in patients with versus without adjuvant chemotherapy in the subgroup of patients with more than two metastatic lesions and/or an abnormally high preoperative CEA level.
See this image and copyright information in PMC

References

    1. Colucci G., Gebbia V., Paoletti G. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the gruppo oncologico dell'italia meridionale. J. Clin. Oncol. 2005;23:4866–4875. - PubMed
    1. Giantonio B.J., Catalano P.J., Meropol N.J. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 2007;25:1539–1544. - PubMed
    1. Grothey A., Sargent D., Goldberg R.M., Schmoll H.J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 2004;22:1209–1214. - PubMed
    1. Hurwitz H., Fehrenbacher L., Novotny W. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004;350:2335–2342. - PubMed
    1. Saltz L.B., Clarke S., Díaz-Rubio E. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 2008;26:2013–2019. - PubMed